Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain; Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Neuropharmacology. 2017 Nov;126:48-57. doi: 10.1016/j.neuropharm.2017.08.027. Epub 2017 Aug 26.
The study of psychiatric disorders usually focuses on emotional symptoms assessment. However, cognitive deficiencies frequently constitute the core symptoms, are often poorly controlled and handicap individual's quality of life. Adenosine receptors, through the control of both dopamine and glutamate systems, have been implicated in the pathophysiology of several psychiatric disorders such as schizophrenia and attention deficit/hyperactivity disorder. Indeed, clinical data indicate that poorly responsive schizophrenia patients treated with adenosine adjuvants show improved treatment outcomes. The A adenosine receptor subtype (AR) is highly expressed in brain areas controlling cognition and motivational responses including the striatum, hippocampus and cerebral cortex. Accordingly, we study the role of AR in the regulation of cognitive processes based on a complete cognitive behavioural analysis coupled with the assessment of neurogenesis and sub-synaptic protein expression in adult and middle-aged AR constitutional knockout mice and wild-type littermates. Our results show overall cognitive impairments in AR knockout mice associated with a decrease in new-born hippocampal neuron proliferation and concomitant changes in synaptic protein expression, in both the prefrontal cortex and the hippocampus. These results suggest a deficient adenosine signalling in cognitive processes, thus providing new opportunities for the therapeutic management of cognitive deficits associated with psychiatric disorders.
精神障碍的研究通常集中在情绪症状的评估上。然而,认知缺陷通常构成核心症状,往往难以控制,并影响个体的生活质量。腺苷受体通过控制多巴胺和谷氨酸系统,与几种精神障碍(如精神分裂症和注意缺陷/多动障碍)的病理生理学有关。事实上,临床数据表明,用腺苷佐剂治疗反应不佳的精神分裂症患者的治疗效果得到改善。A 型腺苷受体(AR)在控制认知和动机反应的大脑区域中高度表达,包括纹状体、海马体和大脑皮层。因此,我们基于完整的认知行为分析,并结合对成年和中年 AR 组成型敲除小鼠和野生型同窝仔鼠的神经发生和亚突触蛋白表达的评估,研究了 AR 在认知过程调节中的作用。我们的研究结果表明,AR 敲除小鼠存在整体认知障碍,与海马新生神经元增殖减少以及前额叶皮层和海马体中突触蛋白表达的变化相关。这些结果表明,认知过程中的腺苷信号传递不足,从而为治疗与精神障碍相关的认知缺陷提供了新的机会。